Table 5.

Metabolic parameters of the control and tumor groups treated with saline (CS and TS) or 200 mg/kg Fr-BuVt (CV200 and TV200)

	CS	CV200	TS	TV200
Initial glycaemia (mg/dL)	80.3 ± 1.7	79.0 ± 3.2	82.4 ± 1.4	81.1 ± 2.0
Final glycaemia (mg/dL)	80.0 ± 4.4	77.5 ± 4.4	59.4 ± 2.9 *	81.7 ± 4.0 $
Triglycerides (mg/dL)	107.0 ± 5.0	97.6 ± 4.3	189.7 ± 10.6 *	106.2 ± 5.9 $
FFA (mEq/L)	0.55 ± 0.06	0.42 ± 0.02 *	0.81 ± 0.04 *	0.56 ± 0.05 $
Total cholesterol (mg/dL)	121.5 ± 4.6	120.1 ± 5.9	101.3 ± 5.5 *	118.7 ± 3.2 $
HDL cholesterol (mg/dL)	74.6 ± 2.8	82.2 ± 2.9	52.9 ± 1.3 *	70.6 ± 3.8 $ &
ALT (U/L)	79.1 ± 3.8	73.2 ± 6.7	144.1 ± 8.7 *	81.0 ± 4.06 $
AST (U/L)	286.1 ± 20.2	299.2 ± 24.0	439.0 ± 22.2 *	281.1 ± 16.1 $
Total proteins (g/dL)	6.1 ± 0.1	5.8 ± 0.3	5.1 ± 0.1 *	5.9 ± 0.1 $
Albumin (g/dL)	1.8 ± 0.05	1.92 ± 0.08	1.4 ± 0.05 *	1.7 ± 0.05 $
Lactate (mmol/L)	9.5 ± 0.5	9.28 ± 0.65	12.5 ± 0.9 *	9.4 ± 0.4 $
Hepatic glycogen (g/100 g)	2.9 ± 0.3	2.5 ± 0.4	0.34 ± 0.04 *	2.5 ± 0.2 $
Muscle glycogen (g/100 g)	0.81 ± 0.06	0.85 ± 0.09	0.44 ± 0.07 *	0.68 ± 0.06 $
TNF-α	1.18 ± 0.2	1.0 ± 0.1	9.7 ± 0.9 *	1.6 ± 0.2 $
IL-6	3.4 ± 0.4	3.0 ± 0.5	22.5 ± 0.7*	4.0 ± 0.4 $

Values are expressed as means ± SEM, two-way ANOVA followed by Holm-Sidak post hoc test, p < 0.05 (* vs CS; $ vs TS; & vs CV).